Tatton Consulting supported Sutton-based AI proteomics company Eliptica in its successful application to Advancing precision medicine, which was awarded £664,036 by Innovate UK for the project DCAD – Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics. The project’s total Innovate UK grant across all partners was £679,134.
About the funded R&D project
Proteomics at population scale has historically been limited by cost and by the volume of plasma each test requires. Eliptica’s founders developed an AI-enhanced, ultrafast mass spectrometry method at the Francis Crick Institute that works from very small plasma volumes. Over a 24-month programme with Bruker UK and UK Biobank, the project applies this platform to build a large reference baseline of the human proteome and use it to generate new diagnostic insight into coronary artery disease, where earlier detection changes the treatment options available.
Award details
- Grant to Eliptica: £664,036
- Total project grant (all partners): £679,134
- Competition: Advancing precision medicine
- Competition year: 2023/24
- Project: DCAD – Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics
- Sector: Cardiovascular diagnostics / proteomics
- Independent verification: Innovate UK funded projects transparency dataset (UKRI), published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from Innovate UK’s published record of funded projects.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
